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Introduction: The growing resistance of Acinetobacter to almost all commercially 
available antibiotics is of major concern. Limited therapeutic options are currently available. 
 
Objectives: The aim of the study was to compare the efficacy of sulbactam regime to 
that of polymyxin B in the treatment Acinetobacter infection.   
 
Patients and Methods: This was a retrospective study of case records over one year 
period (1st January 2018 to 31st December 2018) at the Hospital Universiti Sains Malaysia. 
Patients of least 18 years old, with clinical and microbiological evidence of Acinetobacter 
infection, were enrolled in the study. 
 
Results: 34 patients received polymyxin and 38 received either ampicillin-sulbactam 
or cefoperazone-sulbactam.  24 (63.2%) from the nonpolymyxin group achieved clinical 
success while 13 (38.2%) achieved clinical success in the polymyxin group.  26 patients 
(68.4%) treated with nonpolymyxin achieved microbiological success compared to 18 (52.9%) 
treated with polymyxin.  Mortality was lower in the nonpolymyxin group with 17 deaths 
(44.7%) compared to 23 deaths (67.6%) in the polymyxin group.  Multiple logistic regression 
showed that microbiological failure was significantly associated with 30 days in patient 
mortality. 
 
Conclusion: The most important finding of our study is that sulbactam appears to have 
a better efficacy compared to polymyxin in treating Acinetobacter infection.   
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Latarbelakang: Peningkatan ketahanan Acinetobacter terhadap hampir kesemua antibiotik yang 
berada di pasaran merupakan suatu kebimbangan utama. Pada masa ini, terdapat pilihan 
pengubatan yang terhad. 
Objektif: Tujuan utama kajian ini adalah untuk membandingkan keberkesanan amalan sulbactam 
terhadap polymyxin B dalam rawatan jangkitan Acinetobacter. 
Kaedah: Ini merupakan kajian retrospektif rekod kes dalam jangkamasa setahun (1 Januari 2018 
hingga 31 Disember 2018) di Hospital Universiti Sains Malaysia. Kajian ini melibatkan pesakit 
yang berumur sekurang-kurangnya 18 tahun, dan mempunyai bukti klinikal dan mikrobiologikal 
jangkitan Acinetobacter. 
Keputusan: 34 pesakit menerima polimiksin dan 38 telah menerima sama ada ampicillin-
sulbactam atau cefoperazone-sulbactam. 24 (63.2%) daripada kumpulan bukan polymyxin 
mencapai kejayaan klinikal manakala 12 (38.2%) mencapai kejayaan klinikal dalam kumpulan 
polymyxin. 26 pesakit (68.4%) yang dirawat dengan bukan polymyxin mencapai kejayaan 
mikrobiologikal berbanding dengan 18 (52.9%) yang dirawat dengan polymyxin. Kematian 
adalah rendah dalam kumpulan bukan polymyxin dengan jumlah 17 sahaja (44.7%) berbanding 
dengan 23 kematian (67.6%) dalam kumpulan polymyxin. Regresi logistik pelbagai menunjukkan 
bahawa kegagalan mikrobiologikal terkait secara signifikan dengan 30 hari kematian pesakit. 
Kesimpulan: Penemuan terpenting kajian kami adalah sulbactam yang sebenarnya lebih berkesan 
daripada polymyxin dalam merawat jangkitan Acinetobacter. 








Background: The growing resistance of Acinetobacter to almost all commercially available 
antibiotics is of major concern. Limited therapeutic options are currently available. 
Objectives: The aim of the study was to compare the efficacy of sulbactam regime to that of 
polymyxin B in the treatment Acinetobacter infection.   
Methods: This was a retrospective study of case records over one year period (1st January 2018 
to 31st December 2018) at the Hospital Universiti Sains Malaysia. Patients of least 18 years old, 
with clinical and microbiological evidence of Acinetobacter infection, were enrolled in the study. 
Results: 34 patients received polymyxin and 38 received either ampicillin-sulbactam or 
cefoperazone-sulbactam.  24 (63.2%) from the nonpolymyxin group achieved clinical success 
while 13 (38.2%) achieved clinical success in the polymyxin group.  26 patients (68.4%) treated 
with nonpolymyxin achieved microbiological success compared to 18 (52.9%) treated with 
polymyxin.  Mortality was lower in the nonpolymyxin group with 17 deaths (44.7%) compared 
to 23 deaths (67.6%) in the polymyxin group.  Multiple logistic regression showed that 
microbiological failure was significantly associated with 30 days in patient mortality. 
Conclusion: The most important finding of our study is that sulbactam appears to have a better 
efficacy compared to polymyxin in treating Acinetobacter infection.   





CHAPTER 1  
INTRODUCTION 
Acinetobacter is a genus of Gram-negative bacteria belonging to the wider class of 
Gammaproteobacteria.  It comprises of more than 50 species, most of which are nonpathogenic 
environmental organisms. The most common infection-causing species is Acinetobacter 
baumannii, followed by Acinetobacter calcoaceticus and Acinetobacter lwoffii. Acinetobacter 
baumannii has the potential of spreading among hospitalized patients by virtue of its ability for 
exogenous colonization of human body (throat, gastrointestinal tract, skin) and its high tolerance 
of difficult conditions (survivability in the environment up to 1 month) (Wendt et al. 1997).   
The ability of Acinetobacter to accumulate diverse mechanisms of resistance, has led to the 
emergence of strains that are resistant to all commercially available antibiotics (Lolans et al., 
2006).  Acinetobacter baumannii forms part of the ESCAPE organisms, which are predominantly 
health care-associated organisms that have the potential for substantial antimicrobial resistance 
(De Rosa et al. 2015, Rice et al. 2008).   
In the year 2011, the European and United States Centres for Disease Control and Prevention 
(ECDC and CDC) joined to propose specific definitions for characterizing drug resistance in 
organisms that cause many health care-associated infections (Magiorakos et al. 2012). The 
following definitions were established based on the extent of resistance to antibiotics that would 
otherwise serve as treatments for Acinetobacter (cephalosporins, fluoroquinolones and 
carbapenems) 
 Multidrug-resistant: isolate is non-susceptible to at least one agent in three or more 
antibiotic classes 
 Extensively drug-resistant: isolate is non-susceptible to at least one agent in all but two or 




 Pandrug-resistant: isolate is non-susceptible to all agents 
As from the 1980s, the resistant strains of Acinetobacter became more and more common causes 
of nosocomial infections globally (Gaynes et al. 2005, Rhomberg et al. 2007, Tatman-Otkun et al. 
2004).  Based on a 2009 report of surveillance data from more than 100 centers worldwide 
(Meropenem Yearly Susceptibility Test Information Collection; MYSTIC), 61 percent 
of Acinetobacter isolates were resistant to ceftazidime and 67 percent were resistant to 
ciprofloxacin (Rhomberg et al. 2009).  Emergent carbapenem-resistant strains have been 
demonstrated by other worldwide studies with high rates of carbapenem resistance in some 
locations (Giske et al. 2008, Jean et al. 2011, Manikal et al. 2003, Peleg et al. 2006, Playford et 
al. 2007).  For instance, the prevalence of carbapenem-resistant Acinetobacter baumannii at two 
teaching hospitals in the UK increased from 47 to 77 percent from 2010 to 2012 (Freeman et al. 
2015) while in one referral hospital in northern Vietnam, more than 90 percent of isolates were 
carbapenem resistant (Van et al. 2014). The reported prevalence of carbapenem resistance 
among Acinetobacter baumannii isolates is also quite high in the countries of the Arab League, 
ranging from 36 to 100 percent (Moghnieh et al. 2018).  The epidemiology of serious hospital-
acquired infections has been influenced by the rising prevalence of antimicrobial resistance 
among Acinetobacter baumannii isolates. One systematic review showed that carbapenem-
resistant and multidrug-resistant Acinetobacter baumannii accounted for 65 and 59 percent, 
respectively, of all hospital-acquired infections among intensive care unit patients in Southeast 
Asia (Teerawattanapong et al. 2018).  
Polymyxin B and polymyxin E (Colistin) are the most commonly used agents for Acinetobacter 
isolates resistant to first-line agents. There are no randomized trials addressing their efficacy, 
largely because they are reserved for use in the setting of highly resistant organisms.  Colistin had 
some success for the treatment of Acinetobacter pneumonia, bacteraemia, and meningitis 




not include a comparator treatment, the pooled clinical response rate for intravenous colistin was 
66%. However, one small series of 20 cases of nosocomial pneumonia that was not included in 
the analysis reported a success rate of only 25 percent (Levin et al. 1999).  Nephrotoxicity is the 
most notorious adverse effect associated with systemic colistin and has been reported in up to 36 
percent of patients (Falagas et al. 2006).  Neurotoxicity is another important side effect but 
consists mainly of paraesthesia and is relatively uncommon. Colistin dosing depends on the 
available preparation and should be adjusted in patients with impaired renal function. Polymyxin 
B is associated with lower rates of nephrotoxicity than Colistin. 
Sulbactam, a beta lactamase inhibitor, has shown to have good in vitro activity against 
Acinetobacter species (Urban et  al. 1993).  In HUSM, sulbactam is available in combination form 
namely as ampicillin-sulbactam and cefoperazone-sulbactam.  Several studies have suggested that 
sulbactam might be effective in Acinetobacter infection.  For example, high dose ampicillin-
sulbactam was evaluated as an alternative treatment of late onset ventilator associated pneumonia 
from multidrug resistant Acinetobacter baumannii (Betrosian et al. 2007).  The aim of the study 
was to evaluate the efficacy and safety of two high dose treatment regiments of ampicillin-
sulbactam for multi-drug resistant Acinetobacter baumannii VAP.  It was a randomised 
prospective trial in Hippokration General Hospital in Athens consisted of 27 patients.  Mortality 
rates did not differ significantly between the two groups.  No major adverse reactions were 
recorded.  The conclusion that the study supported the use of high dose regimen of ampicillin-
sulbactam for MDR Acinetobacter baumannii VAP.  However due to the small sample size, the 
result of the study was not statistically strong. 
A retrospective case series study in Korea evaluated the efficacy of high dose sulbactam treatment 
for ventilator associated pneumonia caused by carbapenem resistant Acinetobacter baumannii 
(Jeong et al. 2016).  The conclusion of the study was that high dose sulbactam could be effective 




common and is associated with a higher mortality with the treatment.  The sample size was small 
and the study was not a randomised clinical trial. 
In 2013, a systematic review and meta-analysis of sulbactam based therapy for Acinetobacter 
baumannii infection was published (Chu et al. 2013).  This meta-analysis consisted of four studies 
three of which were retrospective while one was prospective.  Treatment with sulbactam was 
compared to treatment with other classes of antibiotics.  The results suggested that sulbactam-
based therapy may be efficacious to alternative antimicrobial therapy for the treatment of 
Acinetobacter infection.  However, only a very small number of trials were included and none of 
the trial were randomised trials.  Furthermore the number of participants in the studies was 
relatively small and thus the power of the study was not strong enough. 
Another study compared the efficacy of ampicillin/sulbactam and Colistin in the treatment of 
multidrug resistant Acinetobacter baumannii ventilator associated pneumonia (Betrosian et al. 
2008).  This was a prospective cohort study in 28 adults in the intensive care units in Hippokration 
General Hospital in Athens.  The conclusion was that Colistin and high dose ampicillin/sulbactam 
were comparably safe and effective treatments for critically ill patients with MDR Acinetobacter 
baumannii VAP.  However, the sample size of this study was small and the statistical power of 
this study was weak. 
In addition, one retrospective study compared ampicillin/sulbactam with polymyxin for the 
treatment of infections caused by carbapenem- resistant Acinetobacter species (Oliveira et al. 
2008).  The study consisted of a total of 190 patients and was carried out in 2 large teaching 
hospitals in Brazil.  The findings of the study was that ampicillin/sulbactam appeared to be more 
efficacious than polymyxin, which was an independent factor associated with mortality during 
treatment.  However, the polymyxin group consisted of significantly older patients, more 




Furthermore, a 2003 retrospective study consisted of treating 40 MDR Acinetobacter baumannii 
infected patients with intravenous ampicillin/sulbactam (Levin et al. 2003).  The median dose of 
ampicillin/sulbactam was 6g/3g.  There were no observed adverse effects and that study indicated 
that ampicillin/sulbactam might be a good and safe therapeutic option to treat severe 
Acinetobacter baumannii nosocomial infections.  However the study was not a randomised 
clinical trial. 
In 1998, a prospective study was published whereby sulbactam was evaluated in 40 patients with 
non-life threatening multiresistant Acinetobacter baumannii infection in the Hospital de Bellvitge 
in Barcelona (Corbella et al, 1998).  18 patients received intravenous sulbactam alone versus 24 
who received intravenous ampicillin-sulbactam.  The results of the study suggested that sulbactam 
might prove effective for non-life threatening Acinetobacter baumannii infections.  However, its 
role in the treatment of severe infections was unknown.   
These studies have showed promising results of sulbactam based therapy in Acinetobacter 
infection.  However, to our knowledge, no similar study was carried out in Malaysia before.  We 
wanted to assess the outcomes of treating Acinetobacter infection in our population with 
sulbactam.  The hypothesis was that sulbactam was as effective as polymyxin B in treating 
Acinetobacter infection.  Thus, this study’s results would provide a better insight on the accuracy 







OBJECTIVES OF THE STUDY 
 
GENERAL OBJECTIVE 
 To study the outcomes of patients with Acinetobacter infection. 
 
SPECIFIC OBJECTIVES 
1. To determine the proportion of patients with Acinetobacter infection treated with 
polymyxin versus non polymyxin based treatment. 
2. To determine the association between polymyxin and non polymyxin based therapy among 
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with clinical and microbiological evidence of Acinetobacter infection, were enrolled in the study. 
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cefoperazone-sulbactam.  24 (63.2%) from the nonpolymyxin group achieved clinical success 
while 13 (38.2%) achieved clinical success in the polymyxin group.  26 patients (68.4%) treated 
with nonpolymyxin achieved microbiological success compared to 18 (52.9%) treated with 
polymyxin.  Mortality was lower in the nonpolymyxin group with 17 deaths (44.7%) compared 
to 23 deaths (67.6%) in the polymyxin group.  Multiple logistic regression showed that 
microbiological failure was significantly associated with 30 days in patient mortality. 
Conclusion: The most important finding of our study is that sulbactam appears to have a better 
efficacy compared to polymyxin in treating Acinetobacter infection.   








Acinetobacter species is a recognised pathogen implicated in a wide range of nosocomial 
infections.  Its growing resistance to almost all commercially available antibiotics is of major 
concern.  Till date, there has a lack of randomised clinical trials to evaluate the best antimicrobial 
regimen for treating Acinetobacter infections. In clinical practice, Polymyxin B and Colistin 
(Polymyxin E) are being used.  They have good in vitro activity against many gram negative 
bacilli including Acinetobacter species. The major adverse effects are nephrotoxicity, 
neurotoxicity and neuromuscular blockade (Evans et al. 1999, Horton et al. 1982).  At the Hospital 
Universiti Sains Malaysia, Polymyxin B is the current available therapy for the Acinetobacter 
infection.  It is a relatively expensive treatment and therefore its use is strictly regulated.  
Sulbactam, a beta lactamase inhibitor, has shown to have good in vitro activity against 
Acinetobacter species (Urban et al, 1993).  Some studies have suggested that sulbactam might be 
effective in Acinetobacter infection (Betrosian et al. 2007, Betrosian et al. 2008, Chu et al. 2013, 
Corbella et al. 1998, Jeong et al. 2016, Levin et al. 2003, Oliveira et al. 2008). At our centre, 
sulbactam is available in combination forms namely as ampicillin-sulbactam and cefoperazone-
sulbactam.  Unasyn® is sulbactam combined with ampicillin in a fixed 2:1 ratio while 
sulperazone® is sulbactam combined with cefoperazone in a ratio of 1:1.  Sulbactam is a well-
tolerated drug with the main adverse effects being pain at the site of injection, diarrhoea and rash. 
In addition, the cost of the treatment with sulbactam is affordable to the general public.  The aim 








This was a retrospective study of case records over one year period (1st January 2018 to 31st 
December 2018) at the Hospital Universiti Sains Malaysia (HUSM).  HUSM is a tertiary care 
teaching hospital located in the north east state of Kelantan in Malaysia.  The enrolled cases were 
hospitalised patients who were at least 18 years old with clinical evidence of infection and with 
isolation of Acinetobacter species from a specific culture site.  Those patients who were already 
on treatment with either polymyxin B or sulbactam for other concomitant infection, on the day of 
isolation of Acinetobacter, were excluded.  The demographic, clinical and laboratory data from 
the patient’s file were collected.  The study cohort was divided into two groups namely the 
polymyxin group and the nonpolymyxin group.  Each infection was defined using some specific 
criteria as mentioned below. 
For instance, pneumonia was defined as patient having a new or progressive radiographic 
parenchymal lung infiltrate with some signs that the infiltrate was infectious in origin. This 
required the presence of at least 2 of the following signs: temperature alteration (less than 36°C 
or at least 38.3°C), a white blood cell count less than 5000 cells/mm3 or more than 10,000 
cells/mm3, or purulent-appearing sputum or endotracheal aspirate. Hospital Acquired Pneumonia 
(HAP) referred to the development of parenchymal lung infection after at least 48 hours of 
hospitalisation.  On the other hand, if the infection developed after the patient underwent 
intubation and received mechanical ventilation for at least 48 hours, the condition was termed 






Bloodstream Infection included the primary, secondary and central line associated bloodstream 
infections. 
 Primary bloodstream infection was defined as a laboratory confirmed bloodstream infection 
that was not secondary to an infection at another body site. 
 Secondary bloodstream infection was defined as a bloodstream infection that was thought to 
be seeded from a site-specific infection at another body site. 
 Central line-associated bloodstream infection was defined as a laboratory confirmed 
bloodstream infection where an eligible bloodstream infection organism was identified 
and an eligible central line was present on the laboratory confirmed bloodstream infection 
day of event or the day before. 
Surgical site infection occurred within 30 days of surgery and involved any part of the body deeper 
than the fascia/muscle layers that was opened or manipulated during the operative procedure.  The 
patient had at least one of the following:  
 purulent drainage from a drain that is placed into the organ/space  
 organism(s) identified from fluid or tissue in the organ/space by a culture  
 an abscess or other evidence of infection involving the organ/space that is detected on 
gross anatomical or histopathologic exam, or imaging test evidence suggestive of 
infection. 
Urinary tract infection was defined as patient having at least one of the following signs or 
symptoms:  fever (temperature of at least 38.0°C), suprapubic tenderness, costovertebral angle 
pain or tenderness, urinary urgency, urinary frequency or dysuria. In addition, the patient’s voided 




Meningitis was defined as patient having at least two of the following: fever (temperature of at 
least 38.0°C) or meningeal sign(s), cranial nerve sign(s) with 
 Organism identified from cerebrospinal fluid (CSF) by a culture 
 organism seen on Gram stain of CSF 
 increased white cells, elevated protein, and decreased glucose in CSF (per reporting 
laboratory’s reference range)  
National Early Warning Score 2 (NEWS2) is a scoring system used for the assessment and 
response to acute illness.  Six parameters form the basis of the scoring system: respiratory rate, 
oxygen saturation, systolic blood pressure, heart rate, level of consciousness and temperature.  The 
NEWS2 holds a separate section for scoring oxygen saturations in patients with chronic 
respiratory failure, in whom oxygen saturation of 88-92% are recommended.  The NEWS2 score 
calculated on the day of initiation of polymyxin, ampicillin-sulbactam and cefoperazone-












Table 1: NEWS2 scoring system 
 
(NEWS2 Standardising the assessment on acute illness severity in the NHS, Royal College of Physicians) 
LOW score: an aggregate NEWS2 score of 1–4  
MEDIUM score: an aggregate NEWS2 score of 5 or 6.  
HIGH score: an aggregate NEWS2 score of 7 or more.  
Definition of Outcome Events 
The treatment efficacy was assessed on day 5 of treatment.  It comprised of 3 outcomes: 
microbiological response, clinical response and 30 days in patient mortality.   
The clinical response was defined as  
 Success if signs and symptoms improved and/or a decrease of at least 50% on initial CRP 
at day 5 of treatment. 




The microbiological response was defined as 
 Success if there was eradication of Acinetobacter species from culture at day 5 of 
treatment. 
 Failure if persistence of Acinetobacter species at day 5 of treatment. 
30 days in patient mortality was defined as any death of Acinetobacter infected patients within 30 
days of starting treatment in hospital setting. 
Statistical Analysis 
Data was entered and analysed using SPSS version 24.  The results were expressed in terms of 
numbers and percentages or mean and standard deviation.  The categorical variables were tested 
using the chi square test while the student’s t-test was used for continuous variables.  A p-value 
of <0.05 was considered significant.  In addition, logistic regression analysis was carried out to 
evaluate the potential independent risk factors for mortality. 
Ethical Issue 
This study was conducted in accordance with the principles laid by the 18th World Medical 
Assembly (Helsinky, 1964), and all subsequent amendments.  It was approved by the Human 
Research Ethics Committee of USM (JEPeM) on the 8th April 2019 (Reference number: 
USM/JEPeM/ 19010069).   The official authorisation to access patients’ folders was granted from 
the Director of HUSM.  The Infectious Control and Epidemiology Unit (UKJEH) of HUSM was 
contacted in order to get the list of patients with culture positive for Acinetobacter for the intended 
time period. The patients’ personal identification and clinical data were confidential.  No conflict 
of interest was involved in this study and no payment was given or received from any company 
or organization. All of the information obtained from the medical records was recorded in a 






A total of two hundred and eighteen cases were reviewed.  Among these cases, one hundred and 
forty were either contaminants or colonisers.  Only seventy-eight were Acinetobacter infections.  
Six of them were excluded as they were treated with a different antibiotic (piperacillin-
tazobactam).  Purposive sampling was carried out.  Thirty-four received polymyxin treatment, 
twenty-four received ampicillin-sulbactam and fourteen received cefoperazone-sulbactam (Table 
2).  Thus, the nonpolymyxin group had a total of thirty-eight patients (52.8%).   
The initial sample size calculated was one hundred and forty.  However, at the end of the study, 
only seventy-two cases were obtained.  The exact prevalence of acinetobacter infection in HUSM 
was unknown, so it was difficult to determine the proportion of Acinetobacter infection 
beforehand.  As this was a retrospective study and we were limited in time, we could not afford 
to search for more cases in order to meet the calculated sample size.  Furthermore, there were 
twenty case notes which could not be traced during the study period.  .    
The characteristics of the study population are summarised in the Table 3.  There were forty-six 
(63.9%) males and the mean age was 55.0 years old.  Forty patients (55.6%) were admitted to ICU 
while fifteen (20.8%) were admitted in HDU and seventeen (23.6%) were admitted to general 
wards.  Four (5.6%) had end stage renal disease while three (3.4%) had chronic liver disease. 
Thirty-one (43.1%) were diabetics while eleven (15.3%) had a specific underlying malignant 
condition.  The mean NEWS2 Score of the population was 6.8. Sixty-six (91.7%) were infected 
with multidrug resistant Acinetobacter species. 
The majority of the Acinetobacter infections was ventilator associated pneumonia, with twenty-
four (70.6%) in the polymyxin group versus twenty-one (55.3%) in the nonpolymyxin group 
(Table 4).  Five (14.7%) and nine (23.7%) in the polymyxin and nonpolymyxin group respectively 




while on the other hand there was only one case (2.6%) of urinary tract infection treated in the 
nonpolymyxin group.  Two (5.9%) hospital acquired pneumonia were in the polymyxin group 
while three (7.9%) hospital acquired pneumonia cases were in the nonpolymyxin group. 
In the polymyxin group, the mean age was 50.6 years old compared to 58.9 years old in the 
nonpolymyxin group (Table 5).  The mean NEWS2 score of the polymyxin group was higher 
compared to that of the nonpolymyxin group (8.1 vs. 5.6).  Seventeen (50%) in the polymyxin 
group had septic shock compared to three (7.9%) in the nonpolymyxin group.  Thirty-three cases 
(97.1%) of multidrug resistant acinetobacter infection were present in the polymyxin group 
compared to thirty-three (86.8%) in the other group.  There were more diabetics with twenty 
(52.6%) in the nonpolymyxin group versus eleven (32.4%) in the polymyxin group.  Two patients 
(5.9%) had end stage renal disease in the polymyxin group and there were two patients (5.3%) in 
the nonpolymyxin group as well.  Chronic liver disease was present in two patients (5.9%) in the 
polymyxin group and one patient (2.6%) in the nonpolymyxin group.   Six (17.6%) had a specific 
underlying malignant condition in the polymyxin group and five (13.2%) in the nonpolymyxin 
group.  Twenty-three (67.6%) were males in the polymyxin group and similarly there were twenty-
three (60.5%) males in the nonpolymyxin group.  Twenty-four (70.6%) in the polymyxin group 
required ICU admission compared to sixteen (42.1%) in the nonpolymyxin group.  The mean 
number of days between isolation of Acinetobacter and start of treatment in both group is almost 
similar: 1.79 days in the polymyxin group vs. 1.42 days in the nonpolymyxin group. 
Twenty-four (63.2%) from the nonpolymyxin group achieved clinical success while in the 
polymyxin group only thirteen (38.2%) achieved clinical success (Table 6).  Twenty-six (68.4%) 
achieved microbiological success in the nonpolymyxin group versus eighteen (52.9%) in the 
polymyxin group.  Mortality was lower in the nonpolymyxin group with seventeen deaths (44.7%) 




The logistic regression analysis results for the 30-day in patient mortality is shown in Table 7.  
Based on p-value <0.25, the following variables were selected to multiple logistic regression 
analysis: NEWS2 score, male gender, malignancy, septic shock, polymyxin group, and 
microbiological outcome. 
By using method Forward LR for variable selection, variable microbiological outcome remained 
in the model for analysis multiple logistic regression (Table 8).  Thus, microbiological failure was 
significantly associated with the 30-days in patient mortality. 
 
DISCUSSION 
Acinetobacter is known to be one of the most frequent infective organisms in intensive care units.  
One study showed that 54.9% of Acinetobacter species isolates were obtained from ICUs, 36.7% 
and 8.4% from the medical and surgical units respectively (Uwingabiye et al. 2016).  Another 
study noted that Acinetobacter baumannii was more frequently associated with infection among 
patients in the ICU (63.9%) compared to patients admitted to medical (52.8%) and to surgical 
wards (52.9%) (Villar et al. 2014).  Similarly, our study found a predominance of Acinetobacter 
infections in intensive care unit.  Forty patients (55.6%) were from ICU while fifteen (20.8%) 
were from HDU and seventeen (23.6%) were from general wards.   
The majority of the Acinetobacter infections was ventilator associated pneumonia, with twenty-
four patients (70.6%) in the polymyxin group versus twenty-one (55.3%) in the nonpolymyxin 
group.  Five (14.7%) and nine (23.7%) in the polymyxin and nonpolymyxin group respectively 
had bloodstream infection.  Our study was in concordance with other studies whereby VAP was 
proved to be the most common Acinetobacter infection.  For instance, one study showed that VAP 




another study concluded that pneumonia was the most common site of “Acinetobacter baumannii” 
infection (53.1%) (Castilho et al. 2017). 
There was one case (2.9%) of multidrug resistant Acinetobacter meningitis in our study which 
was detected in the CSF of a 22-year-old patient who underwent neurosurgical intervention for 
pineal gland tumour.  The patient was treated with polymyxin but unfortunately, the treatment 
was unsuccessful and the patient passed away in ICU.  This case outlines the difficulty in treating 
Acinetobacter meningitis and highlights its associated high mortality rate.  Chen et al. (2005) 
noted a 30% mortality rate among patients with Acinetobacter meningitis while Rodriguez et al. 
(2008) noted a mortality rate of 33.3% in patients with nosocomial neurosurgical meningitis. 
It has been a common practice at our hospital to use polymyxin for the younger and more severely 
ill patient infected with Acinetobacter in order to maximise their prospect of cure and survival.  
This was evidenced by our data results that showed a lower mean age in the polymyxin group 
(58.9 years vs. 50.6 years) but with a higher percentage of septic shock (50% vs. 7.9%).   
43.1% of the study population were diabetics.  Even though there were more diabetics in the 
nonpolymyxin group than in the polymyxin group (52.6% vs. 32.4%), our study did not show any 
relationship between diabetes and the outcomes in the two groups.  Furthermore, diabetes did not 
have any significant impact on the mortality.  This is in contrast to the study led by Leung et al. 
(2019) which found that mortality was higher in diabetic patient with Acinetobacter infection. 
In terms of outcomes, the nonpolymyxin group fared better compared to the polymyxin group.  
Twenty-four patients (63.2%) from nonpolymyxin group achieved clinical success while in the 
polymyxin group only thirteen (38.2%) achieved clinical success. This success achieved statistical 
significance (p=0.035). Levin et al. (2003) studied twelve patients with ampicillin-sulbactam and 
the results showed 67.5% had clinical improvement. Corbella and al. (1998) treated forty-two 




improvement in 92.9%.  Thus, our clinical outcome is consistent with these studies that used 
sulbactam as an alternative treatment in Acinetobacter infection. 
Twenty-six patients (68.4%) achieved microbiological success in the nonpolymyxin group versus 
18 (52.9%) in the polymyxin group.  Of note, eight (23.5%) from polymyxin group and five 
(13.2%) from nonpolymyxin group did not have repeated culture samples.  Thus, the 
microbiological outcomes could not be assessed in these thirteen cases.  This could partly explain 
why the microbiological outcome did not achieve statistical significance.  Nevertheless, this result 
showed a better microbiological outcome with the nonpolymyxin therapy.  This is in keeping with 
a study which found that ampicillin-sulbactam treated carbapenem resistant Acinetobacter had a 
cure/improvement rate of 70% (Oliveira et al, 2008).  Another study showed comparable 
bacteriologic success in patients infected with multidrug resistant Acinetobacter baumannii 
treated with ampicillin-sulbactam (61.5%) (Betrosian et al. 2008).   
The overall mortality in this study was forty patients (55.6%).  Likewise, the seven year experience 
of Kanafani et al. (2018) on multidrug resistant Acinetobacter noted a mortality rate ranging from 
52% to 66% among the infected patients.  Furthermore, a prospective study by Sileem et al. (2017) 
showed that the mortality in patients who developed nosocomial Acinetobacter infection was 
50%.  
The nonpolymyxin group had better mortality outcomes with lesser deaths: seventeen (42.5%) 
compared to twenty-three (67.6%) in the polymyxin group.  Although the result was not 
significant (p = 0.051), the trend in mortality outcome was similar to that observed in both 
microbiological and clinical outcomes.  A possible explanation for lesser deaths is the severity of 
the illness in the polymyxin group.  The NEWS2 score was higher in the polymyxin group (8.12 
vs. 5.55) and there were more patients in the polymyxin group admitted to the ICU (70.6% vs. 
42.1%).  In addition 50% of patients treated with polymyxin were in septic shock compared to 




The univariate analysis performed for the 30 days in patient mortality showed the following 
variables as independent risk factors for mortality:  higher NEWS2 score, male gender, 
malignancy, septic shock, polymyxin group and microbiological failure.  Worsening of any 
infection is usually accompanied by multi-organ failure and subsequently death. Hence, the 
association with higher NEWS2 score and septic shock with mortality is plausible.   
An interesting finding of this study is that the gender male was associated with mortality.  One 
study reported that Acinetobacter baumannii infection was more frequent in males (Drault et al. 
2001).  This male predominance was explained by the fact that Acinetobacter baumannii is often 
associated with underlying conditions like smoking, alcohol, diabetes and pneumopathies.  In 
contrast, Uwingabiye et al. (2016) also showed male predominance in their study of Acinetobacter 
infection but no reason was justified.  Within the scope of our study, a reasonable explanation for 
the male predominance was that there were almost twice number of males with malignancy 
compared to females.  36.4% of malignancy cases were found in females compared to 73.6% in 
males. 
Malignancy is obviously an independent risk factor of mortality.  In these cases of Acinetobacter 
infection with malignancy, it is difficult to differentiate between the deaths attributable to 
Acinetobacter infection versus those attributable to the underlying malignancy. 
Following the univariate analysis, a multivariate analysis was performed for the 30-day in patient 
mortality.  The result was that microbiological failure was found to be the only independent factor 
significantly associated with mortality in this study.   
 
LIMITATION AND RECOMMENDATION 
Our study does have its limitations. One of them is that it is a retrospective study. More severely 




study.  This might have contributed for not reaching statistical significance in the microbiological 
and mortality outcomes.  Nevertheless, the number of patients infected with Acinetobacter is 
usually limited and therefore, our results should not be underestimated.  Microbiological failure, 
which was determined five days after start of sulbactam treatment, was significantly associated 
with 30 days mortality. Since microbiological failure is a risk factor of mortality, we advise for 
immediate change of antibiotics once microbiological failure is detected. 
 
CONCLUSION 
To our knowledge, this is the first study in Malaysia comparing polymyxin versus sulbactam based 
therapy in Acinetobacter infection.  The most important finding of our study is that sulbactam 
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Table 2: Number of patients with specific antibiotics treatment 
Group Frequency % 









Total 72 100.0 
 
Table 3: Characteristics of patients with Acinetobacter infections 
Variables  Mean (SD) Frequency (%) 
Age 55.0 (15.8)  
NEWS2 Score 6.8 (2.9)  
ICU admission  40 (55.6) 
Male  46 (63.9) 
End stage renal disease  4 (5.6) 
Chronic liver disease  3 (4.2) 
Diabetes   31 (43.1) 
Malignancy   11 (15.3) 
MDRAI  66 (91.7) 





Table 4: Types of Acinetobacter infections in both polymyxin and non polymyxin group 
Infection  Polymyxin group 
Number of cases (%) 
Non polymyxin group 
Number of cases (%) 
Ventilator associated pneumonia 24 (70.6) 21 (55.3) 
Bloodstream infection 5 (14.7) 9 (23.7) 
Surgical site infection 2 (5.9) 4 (10.5) 
Hospital acquired pneumonia 2 (5.9) 3 (7.9)  
Meningitis 1 (2.9) 0 (0) 
Urinary tract infection 0 (0) 1 (2.6) 
Total 34 (100) 38 (100) 
p- value = 0.328 




 N = 34 
Non polymyxin group 
N = 38 
p-value 
Age  Mean (SD) 50.6 (15.9) 58.9 (14.7) 0.025 
NEWS2 Mean (SD) 8.1 (2.7) 5.6 (2.5) 0.000 
ICU admission 24 (70.6%) 16 (42.1%)  0.003 
Male 23 (67.6%) 23 (60.5%) 0.530 
End stage renal disease 2 (5.9%) 2 (5.3%) 0.909 
Chronic liver disease 2 (5.9%) 1 (2.6%) 0.491 
Diabetes  11 (32.4%) 20 (52.6%) 0.083 
Malignancy  6 (17.6%) 5 (13.2%) 0.597 
Septic shock 17 (50%) 3 (7.9%) 0.000 
MDRAI 33 (97.1%) 33 (86.8%) 0.117 




MDRAI: Multidrug resistant Acinetobacter infection              Days: Number of days between isolation of Acinetobacter and start of treatment 
 
 
Table 6: Clinical, microbiological and mortality outcomes in the study groups 
 Polymyxin group 
N = 34 
Nonpolymyxin group 
N = 38 
p-value 
Clinical    
Success 13 (38.2%) 24 (63.2%) 0.035 
Failure 21 (61.8%) 14 (36.8%)  
Microbiological    
Success 18 (52.9%) 26 (68.4%) 0.403 
Failure   8 (23.5%)   7 (18.4%)  
30 days Mortality    
Alive 11 (32.4%) 21 (55.3%) 0.051 









Table 7: Simple logistic regression for 30 days in patient mortality 




0.95 (0.72, 1.24) 
0.490 
0.691 
ICU admission 0.82 (0.25,2.72) 0.739 
Male 1.81 (0.69,4.80) 0.230 
End stage renal disease 2.51 (0.25,25.40) 0.435 
Chronic liver disease 0.39 (0.03,4.44) 0.444 
Diabetes  0.95 (0.37,2.43) 0.915 
Malignancy  2.42 (0.59,9.99) 0.223 
Non MDRAI 0.37 (0.07,2.16) 0.268 
Septic shock 3.24 (1.03,10.22) 0.045 
Polymyxin 0.39 (0.15,1.01) 0.053 
Microbiological outcome 0.09 (0.02,0.44) 0.003 
 
 
Table 8:  Multiple logistic regression analysis for 30 day in patient mortality 
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Introduction 
Acinetobacter species is a recognised pathogen implicated in a wide range of clinical diseases 
such as blood stream infection, pneumonia, surgical site infection, meningitis, urinary tract 
infection, intravascular devices and implant-related infections.  Its growing resistance to almost 
all commercially available antibiotics (carbapenem, cephalosporin, aminoglycoside, 
fluoroquinolone) is causing a severe treatment problem.  Currently, there are limited therapeutic 
options are available against these infections.  Polymyxin B and polymyxin E (Colistin) are the 
available therapies for the Acinetobacter infection. At the Hospital universiti Sains Malaysia, 
polymyxin B is the current drug used for Acinetobacter infections.  However, there are major 
adverse effects associated with it as nephrotoxicity, neurotoxicity and neuromuscular blockade.  




Acinetobacter species.  Some studies have suggested that sulbactam might be effective in 
Acinetobacter infection.  At our centre, sulbactam is available in combination with ampicillin in 
a fixed ratio 2:1 known as Ampicillin-sulbactam.  It is a well-tolerated drug with the main adverse 
effects being pain at the site of injection, diarrhoea and rash.  The aim of the study is to assess the 
clinical efficacy of high dose regimen ampicillin-sulbactam compared to polymyxin B in 
Acinetobacter infection. 
Problem statement & Study rationale 
To compare the efficacy of sulbactam-ampicillin versus polymyxin B in Acinetobacter infection. 
To reduce the usage of polymyxin B as well as to provide an alternative to polymyxin B. 
Research Question(s) 




To study the health outcomes of patients infected with Acinetobacter infection 
Specific  
3. To determine the proportion of patients with Acinetobacter infection treated with 
polymyxin versus non polymyxin based treatment. 
4. To determine the association between polymyxin and non polymyxin based therapy among 






In 2006, Betrosian et al evaluated high dose ampicillin-sulbactam as an alternative treatment of 
late onset ventilator associated pneumonia from multidrug resistant Acinetobacter baumannii.  
The aim of the study was to evaluate the efficacy and safety of 2 high dose treatment regiments 
of ampicillin-sulbactam for multi-drug resistant Acinetobacter baumannii VAP.  It was a 
randomised prospective trial in Hippokration General Hospital in Athens consisted of 27 patients.  
Mortality rates did not differ significantly between the two groups.  No major adverse reactions 
were recorded.  The conclusion that the study supported the use of high dose regimen of 
ampicillin-sulbactam for MDR Acinetobacter baumannii VAP.  However due to the small sample 
size, the result of the study was not statistically strong. 
A retrospective study lead by Oliveira et al in 2007 compared ampicillin/sulbactam with 
polymyxin for the treatment of infections caused by carbapenem- resistant Acinetobacter species.  
The study consisted of a total of 190 patients and was carried out in 2 large teaching hospitals in 
Brazil.  The findings of the study was that ampicillin/sulbactam appeared to be more efficacious 
than polymyxin, which was an independent factor associated with mortality during treatment.  
However, the polymyxin group consisted of significantly older patients, more frequently 
submitted to surgical procedures and had more patients with cancer. 
Another study by Betrosian et al in 2008 compared the efficacy of ampicillin/sulbactam and 
Colistin in the treatment of multidrug resistant Acinetobacter baumannii ventilator associated 
pneumonia.  This was a prospective cohort study in 28 adults in the intensive care units in 
Hippokration General Hospital in Athens.  The conclusion was that Colistin and high dose 
ampicillin/sulbactam were comparably safe and effective treatments for critically ill patients with 
MDR Acinetobacter baumannii VAP.  However, the sample size of this study was small and the 




Levin et al lead a retrospective study in 2002 at the University Sao Paolo, Brazil.  It consisted of 
forty consecutive patients with nosocomial infection caused by MDR Acinetobacter baumannii, 
who were treated with intravenous ampicillin/sulbactam.  The median dose of 
ampicillin/sulbactam was 6g/3g.  There were no observed adverse effects and that study indicated 
that ampicillin/sulbactam might be a good and safe therapeutic option to treat severe 
Acinetobacter baumaanii nosocomial infections.  However the study was not a randomised clinical 
trial. 
In 1998 Corbella et al published a prospective study whereby sulbactam was evaluated in 42 
patients with non-life threatening multiresistant Acinetobacter baumannii infection in the Hospital 
de Bellvitge in Barcelona.  18 patients received intravenous sulbactam alone versus 24 who 
received intravenous ampicillin-sulbactam.  The results of the study suggested that sulbactam 
might prove effective for non-life threatening Acinetobacter baumannii infections.  However its 
role in the treatment of severe infections was unknown.   
A retrospective case series study was conducted by In Beom Jeong et al in 2016 in Korea evaluated 
the efficacy of high dose sulbactam treatment for ventilator associated pneumonia caused by 
carbapenem resistant Acinetobacter baumannii (CRAB).  The conclusion of the study was that 
high dose sulbactam could be effective for the treatment of CRAB ventilator associated 
pneumonia.  However early clinical failure was common and is associated with a higher mortality 
with the treatment.  The sample size was small and the study was not a randomised clinical trial.  
In 2012 Haiqing et al published a systematic review and meta-analysis of sulbactam based therapy 
for Acinetobacter baumannii infection.  The meta-analysis consisted of four studies three of which 
were retrospective while one was prospective.  Treatment with sulbactam was compared to 
treatment with other classes of antibiotics.  The results suggested that sulbactam-based therapy 




infection.  However, only a very small number of trials were included and none of the trial were 
randomised trials.  Furthermore the number of participants in the studies were relatively small and 
thus the power of the study was not strong enough. 
Justification of study: 
● To provide a baseline study for future research in HUSM involving Acinetobacter. 
● To assess the efficacy of sulbactam in Acinetobacter infections and compare to other 
international studies done previously. 
Research design 
Retrospective study over 1 year (1st January 2018 to 31st December 2018) 
Study area 
Hospital Universiti Sains Malaysia 
Study population 
Adult patients admitted to the ward, Intensive Care Unit or High dependency Unit of Hospital 
Universiti Sains Malaysia. 
Inclusion criteria 
 Evidence of infection  
 Isolation of Acinetobacter from culture. 








 Patients already on treatment with either polymyxin B or sulbactam-ampicillin for 
concomitant infections on the day of diagnosis of Acinetobacter infection will be excluded. 
Sample size estimation 
Sample size will be calculated by using 2 proportion formula as shown below.  




Patient related factors:        
Success 
Betrosian et al. Efficacy and safety 
of high dose ampicillin/sulbactam 
vs. Colistin as monotherapy for 
treatment of multidrug resistant 
Acinetobacter baumannii 







With anticipation of drop outs and incomplete data, the sample size was estimated to a total of 
140 with 70 subjects in each arm. 
According to UKJEH (Infectious Control and Epidemiology Unit), around 490 cases of 
Acinetobacter were detected in Hospital Universiti Sains Malaysia in the year 2018.  We are 











Data will be entered and analysed using SPSS version 24. Descriptive statistics will be used to 
summarise the socio-demographic characteristics of subjects. Numerical data will be presented as 
mean (SD) or median (IQR) based on their normality distribution. Categorical data will be 
presented as frequency (percentage).  
JEPeM-USM Review Panel and regulatory authorities may review study data if required. 
 
 
Start by getting the ethical approval for the study from JEPem-USM  Panel.
Request official permission from the Director of HUSM to access patients’ folders.
Contact with the Infectious Control and Epidemiology Unit (UKJEH) in USM to get the list of 
patients infected by “Acinetobacter” from 1st  January 2018 to 31st December 2018.
Access the patients’ folders from the Hospital Records office for data collection.
All the data will be recorded in a data collection form (Table 1).
Statistical analysis and report preparation.
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Table 9: Data collection form 
Date of admission   /   /      
Unit admitted ICU HDU Ward    
Gender Male Female     
Age       
NEWS (2) Score       
Comorbid       
ESRF Yes No     
Diabetes Yes No     
Hep B/C/ 
Liver cirrhosis 
Yes No     
Malignancy Yes No     
















    












      
Date of start of 
treatment 
      
No. of days       
Septic shock Yes No     
Microbiology Yes No     
CRP  Yes No     
S/S Yes No     
30 days in patient 
mortality 





ESRF – defined as any individual requiring regular dialysis on a permanent basis. 
Hepatitis B - defined as any person infected with hepatitis B virus evidenced by the presence of 
HBsAg (Hepatitis B Surface Antigen). 
Hepatits C – defined as any person infected with hepatitis C virus with HCV antibody positive 
and HCV viral load detectable.  
Liver cirrhosis- defined as any patient with ultrasound confirmation of liver cirrhosis. 
Malignancy- malignant tumour affecting any system: hematological, gastro intestinal, thyroid, 
gynecological, pulmonary, hepatic, cerebral and osteoarticular. 
Acinetobacter MDR - Acinetobacter Multi Drug Resistance – defined as isolate which is non-
susceptible to at least one agent in three or more antibiotic classes. 
No. of days – quantifies the number of days between detection of Acinetobacter infection and start 
of treatment. 
Septic shock – sepsis with either lactate >2 mmol/L despite adequate fluid resuscitation or the 
patient is requiring vasopressors to maintain a mean arterial pressure of at least 65mmHg. 
Microbiology – microbiological eradication of Acinetobacter at day 5 of treatment. 
CRP – decrease of at least 50% of initial CRP level at day 5 of treatment. 
S/S – resolution of signs and symptoms of patients at day 5 of treatment. 
30 days in patient mortality – defined as any patient who died in hospital within 30 days period 
after starting treatment. 
NEWS2 is the latest version of the National Early Warning Score (NEWS), first produced in 2012 
and updated in December 2017, which advocates a system to standardize the assessment and 




The NEWS is based on a simple aggregate scoring system in which a score is allocated to 
physiological measurements, already recorded in routine practice, when patients present to, or are 
being monitored in hospital. Six simple physiological parameters form the basis of the scoring 
system: 
• respiration rate 
• oxygen saturation 
• systolic blood pressure 
• pulse rate 
• level of consciousness or new confusion 
• temperature 
The NEWS (2) chart highlights that patients on supplemental oxygen score an additional 2 points, 
and holds a separate section for scoring O2 saturations in patients with chronic respiratory failure, 
in whom O2 saturation of 88-92% are recommended. 
The NEWS2 score calculated on the day of initiation of either polymyxin or Ampicillin-sulbactam 

















Table 10: NEWS2 Scoring System 
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duplication gene. 
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Latarbelakang: Peningkatan ketahanan Acinetobacter terhadap hampir kesemua antibiotik yang 
berada di pasaran merupakan suatu kebimbangan utama. Pada masa ini, terdapat pilihan 
pengubatan yang terhad. 
Objektif: Tujuan utama kajian ini adalah untuk membandingkan keberkesanan amalan sulbactam 
terhadap polymyxin B dalam rawatan jangkitan Acinetobacter. 
Kaedah: Ini merupakan kajian retrospektif rekod kes dalam jangkamasa setahun (1 Januari 2018 
hingga 31 Disember 2018) di Hospital Universiti Sains Malaysia. Kajian ini melibatkan pesakit 
yang berumur sekurang-kurangnya 18 tahun, dan mempunyai bukti klinikal dan mikrobiologikal 
jangkitan Acinetobacter. 
Keputusan: 34 pesakit menerima polimiksin dan 38 telah menerima sama ada ampicillin-
sulbactam atau cefoperazone-sulbactam. 24 (63.2%) daripada kumpulan bukan polymyxin 
mencapai kejayaan klinikal manakala 12 (38.2%) mencapai kejayaan klinikal dalam kumpulan 
polymyxin. 26 pesakit (68.4%) yang dirawat dengan bukan polymyxin mencapai kejayaan 
mikrobiologikal berbanding dengan 18 (52.9%) yang dirawat dengan polymyxin. Kematian 
adalah rendah dalam kumpulan bukan polymyxin dengan jumlah 17 sahaja (44.7%) berbanding 
dengan 23 kematian (67.6%) dalam kumpulan polymyxin. Regresi logistik pelbagai menunjukkan 
bahawa kegagalan mikrobiologikal terkait secara signifikan dengan 30 hari kematian pesakit. 
Kesimpulan: Penemuan terpenting kajian kami adalah sulbactam yang sebenarnya lebih berkesan 
daripada polymyxin dalam merawat jangkitan Acinetobacter. 








Background: The growing resistance of Acinetobacter to almost all commercially available 
antibiotics is of major concern. Limited therapeutic options are currently available. 
Objectives: The aim of the study was to compare the efficacy of sulbactam regime to that of 
polymyxin B in the treatment Acinetobacter infection.   
Methods: This was a retrospective study of case records over one year period (1st January 2018 
to 31st December 2018) at the Hospital Universiti Sains Malaysia. Patients of least 18 years old, 
with clinical and microbiological evidence of Acinetobacter infection, were enrolled in the study. 
Results: 34 patients received polymyxin and 38 received either ampicillin-sulbactam or 
cefoperazone-sulbactam.  24 (63.2%) from the nonpolymyxin group achieved clinical success 
while 13 (38.2%) achieved clinical success in the polymyxin group.  26 patients (68.4%) treated 
with nonpolymyxin achieved microbiological success compared to 18 (52.9%) treated with 
polymyxin.  Mortality was lower in the nonpolymyxin group with 17 deaths (44.7%) compared 
to 23 deaths (67.6%) in the polymyxin group.  Multiple logistic regression showed that 
microbiological failure was significantly associated with 30 days in patient mortality. 
Conclusion: The most important finding of our study is that sulbactam appears to have a better 
efficacy compared to polymyxin in treating Acinetobacter infection.   





CHAPTER 1  
INTRODUCTION 
Acinetobacter is a genus of Gram-negative bacteria belonging to the wider class of 
Gammaproteobacteria.  It comprises of more than 50 species, most of which are nonpathogenic 
environmental organisms. The most common infection-causing species is Acinetobacter 
baumannii, followed by Acinetobacter calcoaceticus and Acinetobacter lwoffii. Acinetobacter 
baumannii has the potential of spreading among hospitalized patients by virtue of its ability for 
exogenous colonization of human body (throat, gastrointestinal tract, skin) and its high tolerance 
of difficult conditions (survivability in the environment up to 1 month) (Wendt et al. 1997).   
The ability of Acinetobacter to accumulate diverse mechanisms of resistance, has led to the 
emergence of strains that are resistant to all commercially available antibiotics (Lolans et al., 
2006).  Acinetobacter baumannii forms part of the ESCAPE organisms, which are predominantly 
health care-associated organisms that have the potential for substantial antimicrobial resistance 
(De Rosa et al. 2015, Rice et al. 2008).   
In the year 2011, the European and United States Centres for Disease Control and Prevention 
(ECDC and CDC) joined to propose specific definitions for characterizing drug resistance in 
organisms that cause many health care-associated infections (Magiorakos et al. 2012). The 
following definitions were established based on the extent of resistance to antibiotics that would 
otherwise serve as treatments for Acinetobacter (cephalosporins, fluoroquinolones and 
carbapenems) 
 Multidrug-resistant: isolate is non-susceptible to at least one agent in three or more 
antibiotic classes 
 Extensively drug-resistant: isolate is non-susceptible to at least one agent in all but two or 




 Pandrug-resistant: isolate is non-susceptible to all agents 
As from the 1980s, the resistant strains of Acinetobacter became more and more common causes 
of nosocomial infections globally (Gaynes et al. 2005, Rhomberg et al. 2007, Tatman-Otkun et al. 
2004).  Based on a 2009 report of surveillance data from more than 100 centers worldwide 
(Meropenem Yearly Susceptibility Test Information Collection; MYSTIC), 61 percent 
of Acinetobacter isolates were resistant to ceftazidime and 67 percent were resistant to 
ciprofloxacin (Rhomberg et al. 2009).  Emergent carbapenem-resistant strains have been 
demonstrated by other worldwide studies with high rates of carbapenem resistance in some 
locations (Giske et al. 2008, Jean et al. 2011, Manikal et al. 2003, Peleg et al. 2006, Playford et 
al. 2007).  For instance, the prevalence of carbapenem-resistant Acinetobacter baumannii at two 
teaching hospitals in the UK increased from 47 to 77 percent from 2010 to 2012 (Freeman et al. 
2015) while in one referral hospital in northern Vietnam, more than 90 percent of isolates were 
carbapenem resistant (Van et al. 2014). The reported prevalence of carbapenem resistance 
among Acinetobacter baumannii isolates is also quite high in the countries of the Arab League, 
ranging from 36 to 100 percent (Moghnieh et al. 2018).  The epidemiology of serious hospital-
acquired infections has been influenced by the rising prevalence of antimicrobial resistance 
among Acinetobacter baumannii isolates. One systematic review showed that carbapenem-
resistant and multidrug-resistant Acinetobacter baumannii accounted for 65 and 59 percent, 
respectively, of all hospital-acquired infections among intensive care unit patients in Southeast 
Asia (Teerawattanapong et al. 2018).  
Polymyxin B and polymyxin E (Colistin) are the most commonly used agents for Acinetobacter 
isolates resistant to first-line agents. There are no randomized trials addressing their efficacy, 
largely because they are reserved for use in the setting of highly resistant organisms.  Colistin had 
some success for the treatment of Acinetobacter pneumonia, bacteraemia, and meningitis 




not include a comparator treatment, the pooled clinical response rate for intravenous colistin was 
66%. However, one small series of 20 cases of nosocomial pneumonia that was not included in 
the analysis reported a success rate of only 25 percent (Levin et al. 1999).  Nephrotoxicity is the 
most notorious adverse effect associated with systemic colistin and has been reported in up to 36 
percent of patients (Falagas et al. 2006).  Neurotoxicity is another important side effect but 
consists mainly of paraesthesia and is relatively uncommon. Colistin dosing depends on the 
available preparation and should be adjusted in patients with impaired renal function. Polymyxin 
B is associated with lower rates of nephrotoxicity than Colistin. 
Sulbactam, a beta lactamase inhibitor, has shown to have good in vitro activity against 
Acinetobacter species (Urban et  al. 1993).  In HUSM, sulbactam is available in combination form 
namely as ampicillin-sulbactam and cefoperazone-sulbactam.  Several studies have suggested that 
sulbactam might be effective in Acinetobacter infection.  For example, high dose ampicillin-
sulbactam was evaluated as an alternative treatment of late onset ventilator associated pneumonia 
from multidrug resistant Acinetobacter baumannii (Betrosian et al. 2007).  The aim of the study 
was to evaluate the efficacy and safety of two high dose treatment regiments of ampicillin-
sulbactam for multi-drug resistant Acinetobacter baumannii VAP.  It was a randomised 
prospective trial in Hippokration General Hospital in Athens consisted of 27 patients.  Mortality 
rates did not differ significantly between the two groups.  No major adverse reactions were 
recorded.  The conclusion that the study supported the use of high dose regimen of ampicillin-
sulbactam for MDR Acinetobacter baumannii VAP.  However due to the small sample size, the 
result of the study was not statistically strong. 
A retrospective case series study in Korea evaluated the efficacy of high dose sulbactam treatment 
for ventilator associated pneumonia caused by carbapenem resistant Acinetobacter baumannii 
(Jeong et al. 2016).  The conclusion of the study was that high dose sulbactam could be effective 




common and is associated with a higher mortality with the treatment.  The sample size was small 
and the study was not a randomised clinical trial. 
In 2013, a systematic review and meta-analysis of sulbactam based therapy for Acinetobacter 
baumannii infection was published (Chu et al. 2013).  This meta-analysis consisted of four studies 
three of which were retrospective while one was prospective.  Treatment with sulbactam was 
compared to treatment with other classes of antibiotics.  The results suggested that sulbactam-
based therapy may be efficacious to alternative antimicrobial therapy for the treatment of 
Acinetobacter infection.  However, only a very small number of trials were included and none of 
the trial were randomised trials.  Furthermore the number of participants in the studies was 
relatively small and thus the power of the study was not strong enough. 
Another study compared the efficacy of ampicillin/sulbactam and Colistin in the treatment of 
multidrug resistant Acinetobacter baumannii ventilator associated pneumonia (Betrosian et al. 
2008).  This was a prospective cohort study in 28 adults in the intensive care units in Hippokration 
General Hospital in Athens.  The conclusion was that Colistin and high dose ampicillin/sulbactam 
were comparably safe and effective treatments for critically ill patients with MDR Acinetobacter 
baumannii VAP.  However, the sample size of this study was small and the statistical power of 
this study was weak. 
In addition, one retrospective study compared ampicillin/sulbactam with polymyxin for the 
treatment of infections caused by carbapenem- resistant Acinetobacter species (Oliveira et al. 
2008).  The study consisted of a total of 190 patients and was carried out in 2 large teaching 
hospitals in Brazil.  The findings of the study was that ampicillin/sulbactam appeared to be more 
efficacious than polymyxin, which was an independent factor associated with mortality during 
treatment.  However, the polymyxin group consisted of significantly older patients, more 




Furthermore, a 2003 retrospective study consisted of treating 40 MDR Acinetobacter baumannii 
infected patients with intravenous ampicillin/sulbactam (Levin et al. 2003).  The median dose of 
ampicillin/sulbactam was 6g/3g.  There were no observed adverse effects and that study indicated 
that ampicillin/sulbactam might be a good and safe therapeutic option to treat severe 
Acinetobacter baumannii nosocomial infections.  However the study was not a randomised 
clinical trial. 
In 1998, a prospective study was published whereby sulbactam was evaluated in 40 patients with 
non-life threatening multiresistant Acinetobacter baumannii infection in the Hospital de Bellvitge 
in Barcelona (Corbella et al, 1998).  18 patients received intravenous sulbactam alone versus 24 
who received intravenous ampicillin-sulbactam.  The results of the study suggested that sulbactam 
might prove effective for non-life threatening Acinetobacter baumannii infections.  However, its 
role in the treatment of severe infections was unknown.   
These studies have showed promising results of sulbactam based therapy in Acinetobacter 
infection.  However, to our knowledge, no similar study was carried out in Malaysia before.  We 
wanted to assess the outcomes of treating Acinetobacter infection in our population with 
sulbactam.  The hypothesis was that sulbactam was as effective as polymyxin B in treating 
Acinetobacter infection.  Thus, this study’s results would provide a better insight on the accuracy 







OBJECTIVES OF THE STUDY 
 
GENERAL OBJECTIVE 
 To study the outcomes of patients with Acinetobacter infection. 
 
SPECIFIC OBJECTIVES 
1. To determine the proportion of patients with Acinetobacter infection treated with 
polymyxin versus non polymyxin based treatment. 
2. To determine the association between polymyxin and non polymyxin based therapy among 
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Background: The growing resistance of Acinetobacter to almost all commercially available 
antibiotics is of major concern. Limited therapeutic options are currently available. 
Objectives: The aim of the study was to compare the efficacy of sulbactam regime to that of 
polymyxin B in the treatment Acinetobacter infection.   
Methods: This was a retrospective study of case records over one year period (1st January 2018 
to 31st December 2018) at the Hospital Universiti Sains Malaysia. Patients of least 18 years old, 
with clinical and microbiological evidence of Acinetobacter infection, were enrolled in the study. 
Results: 34 patients received polymyxin and 38 received either ampicillin-sulbactam or 
cefoperazone-sulbactam.  24 (63.2%) from the nonpolymyxin group achieved clinical success 
while 13 (38.2%) achieved clinical success in the polymyxin group.  26 patients (68.4%) treated 
with nonpolymyxin achieved microbiological success compared to 18 (52.9%) treated with 
polymyxin.  Mortality was lower in the nonpolymyxin group with 17 deaths (44.7%) compared 
to 23 deaths (67.6%) in the polymyxin group.  Multiple logistic regression showed that 
microbiological failure was significantly associated with 30 days in patient mortality. 
Conclusion: The most important finding of our study is that sulbactam appears to have a better 
efficacy compared to polymyxin in treating Acinetobacter infection.   








Acinetobacter species is a recognised pathogen implicated in a wide range of nosocomial 
infections.  Its growing resistance to almost all commercially available antibiotics is of major 
concern.  Till date, there has a lack of randomised clinical trials to evaluate the best antimicrobial 
regimen for treating Acinetobacter infections. In clinical practice, Polymyxin B and Colistin 
(Polymyxin E) are being used.  They have good in vitro activity against many gram negative 
bacilli including Acinetobacter species. The major adverse effects are nephrotoxicity, 
neurotoxicity and neuromuscular blockade (Evans et al. 1999, Horton et al. 1982).  At the Hospital 
Universiti Sains Malaysia, Polymyxin B is the current available therapy for the Acinetobacter 
infection.  It is a relatively expensive treatment and therefore its use is strictly regulated.  
Sulbactam, a beta lactamase inhibitor, has shown to have good in vitro activity against 
Acinetobacter species (Urban et al, 1993).  Some studies have suggested that sulbactam might be 
effective in Acinetobacter infection (Betrosian et al. 2007, Betrosian et al. 2008, Chu et al. 2013, 
Corbella et al. 1998, Jeong et al. 2016, Levin et al. 2003, Oliveira et al. 2008). At our centre, 
sulbactam is available in combination forms namely as ampicillin-sulbactam and cefoperazone-
sulbactam.  Unasyn® is sulbactam combined with ampicillin in a fixed 2:1 ratio while 
sulperazone® is sulbactam combined with cefoperazone in a ratio of 1:1.  Sulbactam is a well-
tolerated drug with the main adverse effects being pain at the site of injection, diarrhoea and rash. 
In addition, the cost of the treatment with sulbactam is affordable to the general public.  The aim 








This was a retrospective study of case records over one year period (1st January 2018 to 31st 
December 2018) at the Hospital Universiti Sains Malaysia (HUSM).  HUSM is a tertiary care 
teaching hospital located in the north east state of Kelantan in Malaysia.  The enrolled cases were 
hospitalised patients who were at least 18 years old with clinical evidence of infection and with 
isolation of Acinetobacter species from a specific culture site.  Those patients who were already 
on treatment with either polymyxin B or sulbactam for other concomitant infection, on the day of 
isolation of Acinetobacter, were excluded.  The demographic, clinical and laboratory data from 
the patient’s file were collected.  The study cohort was divided into two groups namely the 
polymyxin group and the nonpolymyxin group.  Each infection was defined using some specific 
criteria as mentioned below. 
For instance, pneumonia was defined as patient having a new or progressive radiographic 
parenchymal lung infiltrate with some signs that the infiltrate was infectious in origin. This 
required the presence of at least 2 of the following signs: temperature alteration (less than 36°C 
or at least 38.3°C), a white blood cell count less than 5000 cells/mm3 or more than 10,000 
cells/mm3, or purulent-appearing sputum or endotracheal aspirate. Hospital Acquired Pneumonia 
(HAP) referred to the development of parenchymal lung infection after at least 48 hours of 
hospitalisation.  On the other hand, if the infection developed after the patient underwent 
intubation and received mechanical ventilation for at least 48 hours, the condition was termed 






Bloodstream Infection included the primary, secondary and central line associated bloodstream 
infections. 
 Primary bloodstream infection was defined as a laboratory confirmed bloodstream infection 
that was not secondary to an infection at another body site. 
 Secondary bloodstream infection was defined as a bloodstream infection that was thought to 
be seeded from a site-specific infection at another body site. 
 Central line-associated bloodstream infection was defined as a laboratory confirmed 
bloodstream infection where an eligible bloodstream infection organism was identified 
and an eligible central line was present on the laboratory confirmed bloodstream infection 
day of event or the day before. 
Surgical site infection occurred within 30 days of surgery and involved any part of the body deeper 
than the fascia/muscle layers that was opened or manipulated during the operative procedure.  The 
patient had at least one of the following:  
 purulent drainage from a drain that is placed into the organ/space  
 organism(s) identified from fluid or tissue in the organ/space by a culture  
 an abscess or other evidence of infection involving the organ/space that is detected on 
gross anatomical or histopathologic exam, or imaging test evidence suggestive of 
infection. 
Urinary tract infection was defined as patient having at least one of the following signs or 
symptoms:  fever (temperature of at least 38.0°C), suprapubic tenderness, costovertebral angle 
pain or tenderness, urinary urgency, urinary frequency or dysuria. In addition, the patient’s voided 




Meningitis was defined as patient having at least two of the following: fever (temperature of at 
least 38.0°C) or meningeal sign(s), cranial nerve sign(s) with 
 Organism identified from cerebrospinal fluid (CSF) by a culture 
 organism seen on Gram stain of CSF 
 increased white cells, elevated protein, and decreased glucose in CSF (per reporting 
laboratory’s reference range)  
National Early Warning Score 2 (NEWS2) is a scoring system used for the assessment and 
response to acute illness.  Six parameters form the basis of the scoring system: respiratory rate, 
oxygen saturation, systolic blood pressure, heart rate, level of consciousness and temperature.  The 
NEWS2 holds a separate section for scoring oxygen saturations in patients with chronic 
respiratory failure, in whom oxygen saturation of 88-92% are recommended.  The NEWS2 score 
calculated on the day of initiation of polymyxin, ampicillin-sulbactam and cefoperazone-












Table 1: NEWS2 scoring system 
 
(NEWS2 Standardising the assessment on acute illness severity in the NHS, Royal College of Physicians) 
LOW score: an aggregate NEWS2 score of 1–4  
MEDIUM score: an aggregate NEWS2 score of 5 or 6.  
HIGH score: an aggregate NEWS2 score of 7 or more.  
Definition of Outcome Events 
The treatment efficacy was assessed on day 5 of treatment.  It comprised of 3 outcomes: 
microbiological response, clinical response and 30 days in patient mortality.   
The clinical response was defined as  
 Success if signs and symptoms improved and/or a decrease of at least 50% on initial CRP 
at day 5 of treatment. 




The microbiological response was defined as 
 Success if there was eradication of Acinetobacter species from culture at day 5 of 
treatment. 
 Failure if persistence of Acinetobacter species at day 5 of treatment. 
30 days in patient mortality was defined as any death of Acinetobacter infected patients within 30 
days of starting treatment in hospital setting. 
Statistical Analysis 
Data was entered and analysed using SPSS version 24.  The results were expressed in terms of 
numbers and percentages or mean and standard deviation.  The categorical variables were tested 
using the chi square test while the student’s t-test was used for continuous variables.  A p-value 
of <0.05 was considered significant.  In addition, logistic regression analysis was carried out to 
evaluate the potential independent risk factors for mortality. 
Ethical Issue 
This study was conducted in accordance with the principles laid by the 18th World Medical 
Assembly (Helsinky, 1964), and all subsequent amendments.  It was approved by the Human 
Research Ethics Committee of USM (JEPeM) on the 8th April 2019 (Reference number: 
USM/JEPeM/ 19010069).   The official authorisation to access patients’ folders was granted from 
the Director of HUSM.  The Infectious Control and Epidemiology Unit (UKJEH) of HUSM was 
contacted in order to get the list of patients with culture positive for Acinetobacter for the intended 
time period. The patients’ personal identification and clinical data were confidential.  No conflict 
of interest was involved in this study and no payment was given or received from any company 
or organization. All of the information obtained from the medical records was recorded in a 






A total of two hundred and eighteen cases were reviewed.  Among these cases, one hundred and 
forty were either contaminants or colonisers.  Only seventy-eight were Acinetobacter infections.  
Six of them were excluded as they were treated with a different antibiotic (piperacillin-
tazobactam).  Purposive sampling was carried out.  Thirty-four received polymyxin treatment, 
twenty-four received ampicillin-sulbactam and fourteen received cefoperazone-sulbactam (Table 
2).  Thus, the nonpolymyxin group had a total of thirty-eight patients (52.8%).   
The initial sample size calculated was one hundred and forty.  However, at the end of the study, 
only seventy-two cases were obtained.  The exact prevalence of acinetobacter infection in HUSM 
was unknown, so it was difficult to determine the proportion of Acinetobacter infection 
beforehand.  As this was a retrospective study and we were limited in time, we could not afford 
to search for more cases in order to meet the calculated sample size.  Furthermore, there were 
twenty case notes which could not be traced during the study period.  .    
The characteristics of the study population are summarised in the Table 3.  There were forty-six 
(63.9%) males and the mean age was 55.0 years old.  Forty patients (55.6%) were admitted to ICU 
while fifteen (20.8%) were admitted in HDU and seventeen (23.6%) were admitted to general 
wards.  Four (5.6%) had end stage renal disease while three (3.4%) had chronic liver disease. 
Thirty-one (43.1%) were diabetics while eleven (15.3%) had a specific underlying malignant 
condition.  The mean NEWS2 Score of the population was 6.8. Sixty-six (91.7%) were infected 
with multidrug resistant Acinetobacter species. 
The majority of the Acinetobacter infections was ventilator associated pneumonia, with twenty-
four (70.6%) in the polymyxin group versus twenty-one (55.3%) in the nonpolymyxin group 
(Table 4).  Five (14.7%) and nine (23.7%) in the polymyxin and nonpolymyxin group respectively 




while on the other hand there was only one case (2.6%) of urinary tract infection treated in the 
nonpolymyxin group.  Two (5.9%) hospital acquired pneumonia were in the polymyxin group 
while three (7.9%) hospital acquired pneumonia cases were in the nonpolymyxin group. 
In the polymyxin group, the mean age was 50.6 years old compared to 58.9 years old in the 
nonpolymyxin group (Table 5).  The mean NEWS2 score of the polymyxin group was higher 
compared to that of the nonpolymyxin group (8.1 vs. 5.6).  Seventeen (50%) in the polymyxin 
group had septic shock compared to three (7.9%) in the nonpolymyxin group.  Thirty-three cases 
(97.1%) of multidrug resistant acinetobacter infection were present in the polymyxin group 
compared to thirty-three (86.8%) in the other group.  There were more diabetics with twenty 
(52.6%) in the nonpolymyxin group versus eleven (32.4%) in the polymyxin group.  Two patients 
(5.9%) had end stage renal disease in the polymyxin group and there were two patients (5.3%) in 
the nonpolymyxin group as well.  Chronic liver disease was present in two patients (5.9%) in the 
polymyxin group and one patient (2.6%) in the nonpolymyxin group.   Six (17.6%) had a specific 
underlying malignant condition in the polymyxin group and five (13.2%) in the nonpolymyxin 
group.  Twenty-three (67.6%) were males in the polymyxin group and similarly there were twenty-
three (60.5%) males in the nonpolymyxin group.  Twenty-four (70.6%) in the polymyxin group 
required ICU admission compared to sixteen (42.1%) in the nonpolymyxin group.  The mean 
number of days between isolation of Acinetobacter and start of treatment in both group is almost 
similar: 1.79 days in the polymyxin group vs. 1.42 days in the nonpolymyxin group. 
Twenty-four (63.2%) from the nonpolymyxin group achieved clinical success while in the 
polymyxin group only thirteen (38.2%) achieved clinical success (Table 6).  Twenty-six (68.4%) 
achieved microbiological success in the nonpolymyxin group versus eighteen (52.9%) in the 
polymyxin group.  Mortality was lower in the nonpolymyxin group with seventeen deaths (44.7%) 




The logistic regression analysis results for the 30-day in patient mortality is shown in Table 7.  
Based on p-value <0.25, the following variables were selected to multiple logistic regression 
analysis: NEWS2 score, male gender, malignancy, septic shock, polymyxin group, and 
microbiological outcome. 
By using method Forward LR for variable selection, variable microbiological outcome remained 
in the model for analysis multiple logistic regression (Table 8).  Thus, microbiological failure was 
significantly associated with the 30-days in patient mortality. 
 
DISCUSSION 
Acinetobacter is known to be one of the most frequent infective organisms in intensive care units.  
One study showed that 54.9% of Acinetobacter species isolates were obtained from ICUs, 36.7% 
and 8.4% from the medical and surgical units respectively (Uwingabiye et al. 2016).  Another 
study noted that Acinetobacter baumannii was more frequently associated with infection among 
patients in the ICU (63.9%) compared to patients admitted to medical (52.8%) and to surgical 
wards (52.9%) (Villar et al. 2014).  Similarly, our study found a predominance of Acinetobacter 
infections in intensive care unit.  Forty patients (55.6%) were from ICU while fifteen (20.8%) 
were from HDU and seventeen (23.6%) were from general wards.   
The majority of the Acinetobacter infections was ventilator associated pneumonia, with twenty-
four patients (70.6%) in the polymyxin group versus twenty-one (55.3%) in the nonpolymyxin 
group.  Five (14.7%) and nine (23.7%) in the polymyxin and nonpolymyxin group respectively 
had bloodstream infection.  Our study was in concordance with other studies whereby VAP was 
proved to be the most common Acinetobacter infection.  For instance, one study showed that VAP 




another study concluded that pneumonia was the most common site of “Acinetobacter baumannii” 
infection (53.1%) (Castilho et al. 2017). 
There was one case (2.9%) of multidrug resistant Acinetobacter meningitis in our study which 
was detected in the CSF of a 22-year-old patient who underwent neurosurgical intervention for 
pineal gland tumour.  The patient was treated with polymyxin but unfortunately, the treatment 
was unsuccessful and the patient passed away in ICU.  This case outlines the difficulty in treating 
Acinetobacter meningitis and highlights its associated high mortality rate.  Chen et al. (2005) 
noted a 30% mortality rate among patients with Acinetobacter meningitis while Rodriguez et al. 
(2008) noted a mortality rate of 33.3% in patients with nosocomial neurosurgical meningitis. 
It has been a common practice at our hospital to use polymyxin for the younger and more severely 
ill patient infected with Acinetobacter in order to maximise their prospect of cure and survival.  
This was evidenced by our data results that showed a lower mean age in the polymyxin group 
(58.9 years vs. 50.6 years) but with a higher percentage of septic shock (50% vs. 7.9%).   
43.1% of the study population were diabetics.  Even though there were more diabetics in the 
nonpolymyxin group than in the polymyxin group (52.6% vs. 32.4%), our study did not show any 
relationship between diabetes and the outcomes in the two groups.  Furthermore, diabetes did not 
have any significant impact on the mortality.  This is in contrast to the study led by Leung et al. 
(2019) which found that mortality was higher in diabetic patient with Acinetobacter infection. 
In terms of outcomes, the nonpolymyxin group fared better compared to the polymyxin group.  
Twenty-four patients (63.2%) from nonpolymyxin group achieved clinical success while in the 
polymyxin group only thirteen (38.2%) achieved clinical success. This success achieved statistical 
significance (p=0.035). Levin et al. (2003) studied twelve patients with ampicillin-sulbactam and 
the results showed 67.5% had clinical improvement. Corbella and al. (1998) treated forty-two 
cases of non-life threatening Acinetobacter infection with sulbactam and noted a clinical 
